Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy - Barratt, J; Lafayette, R; Kristensen, J (Kidney Int, 2023)